Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.

GS-5806 is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead optimization campaign on a screening hit. The oral absorption properties were optimized by converting to the pyrazolo[1,5-a]-pyrimidine heterocycle, while potency, metabolic, and physicochemical properties were optimized by introducing the para-chloro and aminopyrrolidine groups. A mean EC50 = 0.43 nM was found toward a panel of 75 RSV A and B clinical isolates and dose-dependent antiviral efficacy in the cotton rat model of RSV infection. Oral bioavailability in preclinical species ranged from 46 to 100%, with evidence of efficient penetration into lung tissue. In healthy human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a mean 4.2 log10 reduction in peak viral load and a significant reduction in disease severity compared to placebo. In conclusion, a potent, once daily, oral RSV fusion inhibitor with the potential to treat RSV infection in infants and adults is reported.

[1]  D. M.,et al.  Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. , 2016, The New England journal of medicine.

[2]  Xiaohong Liu,et al.  GS-5806 Inhibits Pre- to Postfusion Conformational Changes of the Respiratory Syncytial Virus Fusion Protein , 2015, Antimicrobial Agents and Chemotherapy.

[3]  Rob Lambkin-Williams,et al.  Oral GS-5806 activity in a respiratory syncytial virus challenge study. , 2014, The New England journal of medicine.

[4]  Eneida A. Mendonça,et al.  Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection , 2014, Pediatrics.

[5]  Nicholas A. Meanwell,et al.  Successful Strategies for the Discovery of Antiviral Drugs , 2013 .

[6]  Thomas J. Raub,et al.  How hydrogen bonds impact P-glycoprotein transport and permeability. , 2012, Bioorganic & medicinal chemistry letters.

[7]  R. Angell,et al.  The Prophylaxis and Treatment with Antiviral Agents of Respiratory Syncytial Virus Infections , 2012, Antiviral chemistry & chemotherapy.

[8]  J. Melero,et al.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. , 2011, Virus research.

[9]  W. Kazmierski.  Antiviral Drugs: From Basic Discovery Through Clinical Trials , 2011 .

[10]  D. Nauwelaers,et al.  Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model , 2010, Antimicrobial Agents and Chemotherapy.

[11]  R. Welliver.  Pharmacotherapy of respiratory syncytial virus infection. , 2010, Current opinion in pharmacology.

[12]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2010, The Lancet.

[13]  H. V. van Vlijmen,et al.  Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein , 2009, Proceedings of the National Academy of Sciences.

[14]  G. Prince,et al.  The cotton rat model of respiratory viral infections. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[15]  P. Openshaw,et al.  Emerging drugs for respiratory syncytial virus infection , 2009, Expert opinion on emerging drugs.

[16]  K. Andries,et al.  Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). , 2008, Journal of medicinal chemistry.

[17]  A. Randolph,et al.  Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. , 2010, The Cochrane database of systematic reviews.

[18]  K. Andries,et al.  Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship. , 2007, Journal of medicinal chemistry.

[19]  O. Ramilo,et al.  The Association Between Respiratory Syncytial Virus Infection and the Development of Childhood Asthma: A Systematic Review of the Literature , 2007, The Pediatric infectious disease journal.

[20]  Robert A. Harris,et al.  1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. , 2007, Journal of medicinal chemistry.

[21]  J. McKew,et al.  Synthesis of pyrazolo[1,5 -α ]pyrimidinone regioisomers , 2007 .

[22]  M. Boeckh,et al.  Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Cihlar,et al.  Small Molecules VP-14637 and JNJ-2408068 Inhibit Respiratory Syncytial Virus Fusion by Similar Mechanisms , 2005, Antimicrobial Agents and Chemotherapy.

[24]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[25]  S. Shevelev,et al.  Liquid-phase synthesis of combinatorial libraries based on 7-trifluoromethyl-substituted pyrazolo[1,5-a]pyrimidine scaffold. , 2005, Journal of combinatorial chemistry.

[26]  N. Meanwell,et al.  Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection , 2004, Antimicrobial Agents and Chemotherapy.

[27]  N. Meanwell,et al.  Orally Active Fusion Inhibitor of Respiratory Syncytial Virus , 2004, Antimicrobial Agents and Chemotherapy.

[28]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[29]  Liang-Shang Gan,et al.  Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR. , 2002, Chemical research in toxicology.